Alyeska Investment Group
FPRX

Alyeska Investment Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Alyeska Investment Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-209,691
Closed -$3.57M – 951
2020
Q4 		$3.57M Buy
+209,691
New +$2.63M 0.05% 321
2018
Q2 		– Sell
-148,661
Closed -$2.55M – 563
2018
Q1 		$2.55M Buy
+148,661
New +$2.9M 0.02% 334
2014
Q1 		– Sell
-127,401
Closed -$2.14M – 422
2013
Q4 		$2.14M Sell
127,401
-99
-0.1% -$1.23K 0.08% 226
2013
Q3 		$1.67M Buy
+127,500
New +$1.72M 0.07% 237

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Alyeska Investment Group's FPRX Position: Q1 2021 in Review

Alyeska Investment Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 209,691 shares — an estimated $3.57M sold.

Alyeska Investment Group first reported a position in FPRX in Q3 2013 and held it in 4 quarters. The position peaked at $3.57M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

  • Alyeska Investment Group reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 209,691 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $3.57M.
  • Alyeska Investment Group first reported a position in Five Prime Therapeutics, Inc. in Q3 2013 and held it in 4 quarters.
  • Alyeska Investment Group's Five Prime Therapeutics, Inc. position peaked at $3.57M in Q4 2020.
  • 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Alyeska Investment Group's 13F filing for Q1 2021, filed 17 May 2021.